Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic ...
An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers ...
Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback